Optimizing Naltrexone for Individuals of East Asian Descent View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2013-2016

ABSTRACT

This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of East Asian descent, an ethnic group most likely to express the positive predictive allele. Detailed Description Recent pharmacogenetic studies have advanced the gene coding for µ-opioid receptors (OPRM1) gene as a potential moderator of responses to naltrexone. The most widely studied polymorphism of the OPRM1 gene is the Asn40Asp single nucleotide polymorphism (SNP), a functional mutation thought to affect receptor activity such that the Asp40 variant binds β-endorphin three times stronger than the Asn40 allele. Recent studies have found that Asp40 carriers have a stronger striatal dopamine response to intravenous alcohol administration and report stronger feelings of alcohol reward. Findings from the COMBINE Study demonstrated that if treated with Medication Management alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared with only 54.8% of Asn40 homozygotes. While these findings are promising, studies have also highlighted allele frequency imbalance as a function of ethnicity such that the Asp40 allele frequency is approximately 20% in Caucasians, 5% in individuals of African Ancestry, and as high as 50% among individuals of East Asian descent. Therefore, to the extent to which this SNP moderates behavioral and clinical responses to NTX, ethnicity must be carefully considered in order to extend the findings from primarily Caucasian samples to ethnic minorities, such as Asian Americans. Preliminary work by our team has found that among individuals of East Asian descent, Asp40 carriers show greater NTX-induced blunting of alcohol craving as well as potentiation of the aversive effects of alcohol. This pilot study also found support for a gene dose-response, such that Asp40Asp individuals showed greater NTX responsivity than those with the Asn40Asp genotype. This study seeks to build upon these preliminary findings by testing heavy drinkers of East Asian descent across three OPRM1 genotypes (Asn40Asn, n = 30; Asn40Asp, n = 30, and Asp40Asp, n = 30). Participants will complete two double-blinded, counterbalanced alcohol infusion and self-administration sessions, one after taking NTX (50 mg/day) and one after taking matched placebo for five days. In each medication condition, participants will complete a functional neuroimaging task examining cue-induced craving for alcohol. This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of Asian descent, an ethnic group most likely to express the positive predictive allele (Asp40). The long-term objective of this research is to optimize alcoholism pharmacotherapy and to address health disparities by advancing pharmacogenetic studies in ethnic minority groups. More... »

URL

https://clinicaltrials.gov/show/NCT02026011

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of East Asian descent, an ethnic group most likely to express the positive predictive allele.\n\nDetailed Description\nRecent pharmacogenetic studies have advanced the gene coding for \u00b5-opioid receptors (OPRM1) gene as a potential moderator of responses to naltrexone. The most widely studied polymorphism of the OPRM1 gene is the Asn40Asp single nucleotide polymorphism (SNP), a functional mutation thought to affect receptor activity such that the Asp40 variant binds \u03b2-endorphin three times stronger than the Asn40 allele. Recent studies have found that Asp40 carriers have a stronger striatal dopamine response to intravenous alcohol administration and report stronger feelings of alcohol reward. Findings from the COMBINE Study demonstrated that if treated with Medication Management alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared with only 54.8% of Asn40 homozygotes. While these findings are promising, studies have also highlighted allele frequency imbalance as a function of ethnicity such that the Asp40 allele frequency is approximately 20% in Caucasians, 5% in individuals of African Ancestry, and as high as 50% among individuals of East Asian descent. Therefore, to the extent to which this SNP moderates behavioral and clinical responses to NTX, ethnicity must be carefully considered in order to extend the findings from primarily Caucasian samples to ethnic minorities, such as Asian Americans. Preliminary work by our team has found that among individuals of East Asian descent, Asp40 carriers show greater NTX-induced blunting of alcohol craving as well as potentiation of the aversive effects of alcohol. This pilot study also found support for a gene dose-response, such that Asp40Asp individuals showed greater NTX responsivity than those with the Asn40Asp genotype. This study seeks to build upon these preliminary findings by testing heavy drinkers of East Asian descent across three OPRM1 genotypes (Asn40Asn, n = 30; Asn40Asp, n = 30, and Asp40Asp, n = 30). Participants will complete two double-blinded, counterbalanced alcohol infusion and self-administration sessions, one after taking NTX (50 mg/day) and one after taking matched placebo for five days. In each medication condition, participants will complete a functional neuroimaging task examining cue-induced craving for alcohol. This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of Asian descent, an ethnic group most likely to express the positive predictive allele (Asp40). The long-term objective of this research is to optimize alcoholism pharmacotherapy and to address health disparities by advancing pharmacogenetic studies in ethnic minority groups.", 
    "endDate": "2016-09-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02026011", 
    "keywords": [
      "optimizing", 
      "East asian", 
      "pharmacogenetics", 
      "OPRM1", 
      "gene", 
      "neural marker", 
      "naltrexone", 
      "individual", 
      "ethnic group", 
      "allele", 
      "pharmacogenetic study", 
      "potential moderator", 
      "single nucleotide polymorphism", 
      "functional mutation", 
      "receptor activity", 
      "variant", 
      "endorphin", 
      "Recent study", 
      "carrier", 
      "striatal dopamine", 
      "alcohol administration", 
      "alcohol reward", 
      "COMBINE study", 
      "medication management", 
      "good clinical outcome", 
      "homozygote", 
      "frequency", 
      "ethnicity", 
      "caucasian", 
      "African ancestry", 
      "clinical response", 
      "NTX", 
      "ethnic minority", 
      "Asian american", 
      "preliminary work", 
      "team", 
      "blunting", 
      "alcohol craving", 
      "potentiation", 
      "aversive effect", 
      "alcohol", 
      "Pilot Project", 
      "responsivity", 
      "genotype", 
      "preliminary finding", 
      "heavy drinker", 
      "infusion", 
      "self-administration", 
      "placebo", 
      "medication", 
      "Functional Neuroimaging", 
      "cue-induced craving", 
      "descent", 
      "long-term objective", 
      "Alcoholism", 
      "health disparity", 
      "ethnic minority group"
    ], 
    "name": "Optimizing Naltrexone for Individuals of East Asian Descent", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02026011"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00015.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.420085.b", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.19006.3e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2013-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/npp.2011.192", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000578926", 
          "https://doi.org/10.1038/npp.2011.192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/acer.13586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099706520"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02026011"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02026011'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02026011'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02026011'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02026011'


 

This table displays all metadata directly associated to this object as RDF triples.

85 TRIPLES      16 PREDICATES      75 URIs      66 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02026011 schema:about anzsrc-for:3053
2 schema:description This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of East Asian descent, an ethnic group most likely to express the positive predictive allele. Detailed Description Recent pharmacogenetic studies have advanced the gene coding for µ-opioid receptors (OPRM1) gene as a potential moderator of responses to naltrexone. The most widely studied polymorphism of the OPRM1 gene is the Asn40Asp single nucleotide polymorphism (SNP), a functional mutation thought to affect receptor activity such that the Asp40 variant binds β-endorphin three times stronger than the Asn40 allele. Recent studies have found that Asp40 carriers have a stronger striatal dopamine response to intravenous alcohol administration and report stronger feelings of alcohol reward. Findings from the COMBINE Study demonstrated that if treated with Medication Management alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared with only 54.8% of Asn40 homozygotes. While these findings are promising, studies have also highlighted allele frequency imbalance as a function of ethnicity such that the Asp40 allele frequency is approximately 20% in Caucasians, 5% in individuals of African Ancestry, and as high as 50% among individuals of East Asian descent. Therefore, to the extent to which this SNP moderates behavioral and clinical responses to NTX, ethnicity must be carefully considered in order to extend the findings from primarily Caucasian samples to ethnic minorities, such as Asian Americans. Preliminary work by our team has found that among individuals of East Asian descent, Asp40 carriers show greater NTX-induced blunting of alcohol craving as well as potentiation of the aversive effects of alcohol. This pilot study also found support for a gene dose-response, such that Asp40Asp individuals showed greater NTX responsivity than those with the Asn40Asp genotype. This study seeks to build upon these preliminary findings by testing heavy drinkers of East Asian descent across three OPRM1 genotypes (Asn40Asn, n = 30; Asn40Asp, n = 30, and Asp40Asp, n = 30). Participants will complete two double-blinded, counterbalanced alcohol infusion and self-administration sessions, one after taking NTX (50 mg/day) and one after taking matched placebo for five days. In each medication condition, participants will complete a functional neuroimaging task examining cue-induced craving for alcohol. This study will elucidate the pharmacogenetic effects of the Asn40Asp SNP of the OPRM1 gene on biobehavioral and neural markers of response to naltrexone in individuals of Asian descent, an ethnic group most likely to express the positive predictive allele (Asp40). The long-term objective of this research is to optimize alcoholism pharmacotherapy and to address health disparities by advancing pharmacogenetic studies in ethnic minority groups.
3 schema:endDate 2016-09-01T00:00:00Z
4 schema:keywords African ancestry
5 Alcoholism
6 Asian american
7 COMBINE study
8 East asian
9 Functional Neuroimaging
10 NTX
11 OPRM1
12 Pilot Project
13 Recent study
14 alcohol
15 alcohol administration
16 alcohol craving
17 alcohol reward
18 allele
19 aversive effect
20 blunting
21 carrier
22 caucasian
23 clinical response
24 cue-induced craving
25 descent
26 endorphin
27 ethnic group
28 ethnic minority
29 ethnic minority group
30 ethnicity
31 frequency
32 functional mutation
33 gene
34 genotype
35 good clinical outcome
36 health disparity
37 heavy drinker
38 homozygote
39 individual
40 infusion
41 long-term objective
42 medication
43 medication management
44 naltrexone
45 neural marker
46 optimizing
47 pharmacogenetic study
48 pharmacogenetics
49 placebo
50 potential moderator
51 potentiation
52 preliminary finding
53 preliminary work
54 receptor activity
55 responsivity
56 self-administration
57 single nucleotide polymorphism
58 striatal dopamine
59 team
60 variant
61 schema:name Optimizing Naltrexone for Individuals of East Asian Descent
62 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02026011
63 schema:sdDatePublished 2019-03-07T15:25
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N096fdd93829949b5a0b6ffdb2b14465d
66 schema:sponsor https://www.grid.ac/institutes/grid.19006.3e
67 https://www.grid.ac/institutes/grid.420085.b
68 schema:startDate 2013-12-01T00:00:00Z
69 schema:subjectOf sg:pub.10.1038/npp.2011.192
70 https://doi.org/10.1111/acer.13586
71 schema:url https://clinicaltrials.gov/show/NCT02026011
72 sgo:license sg:explorer/license/
73 sgo:sdDataset clinical_trials
74 rdf:type schema:MedicalStudy
75 N096fdd93829949b5a0b6ffdb2b14465d schema:name Springer Nature - SN SciGraph project
76 rdf:type schema:Organization
77 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
78 rdf:type schema:DefinedTerm
79 sg:pub.10.1038/npp.2011.192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000578926
80 https://doi.org/10.1038/npp.2011.192
81 rdf:type schema:CreativeWork
82 https://doi.org/10.1111/acer.13586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099706520
83 rdf:type schema:CreativeWork
84 https://www.grid.ac/institutes/grid.19006.3e schema:Organization
85 https://www.grid.ac/institutes/grid.420085.b schema:Organization
 




Preview window. Press ESC to close (or click here)


...